Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot RCT of Cytisine vs NRT+ in Relapsed Smokers
NCT04286295Terminated
- Sponsor
- University of Ottawa Heart Institute
- Start
- Mar 2022
- Primary completion
- Nov 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of cytisinicline in Tobacco Use Disorder (TUD) (2 arms), sponsored by University of Ottawa Heart Institute. Primary endpoint: Feasibility of study at 25 days. Started Mar 2022; status: terminated.
02
Drugs
cytisinicline
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT04286295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04286295.